The Real Decoy-Reference-Cited by-同舟云学术

The Real Decoy

Published:2013-09-27 Issue:8 Volume:113 Page:954-957
ISSN:0009-7330
Container-title:Circulation Research
language:en
Short-container-title:Circ Res

Author:

Yeh Calvin H.¹,Fredenburgh James C.¹,Weitz Jeffrey I.¹

Affiliation:

1. From the Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Canada.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology

Link

https://www.ahajournals.org/doi/pdf/10.1161/CIRCRESAHA.113.302297

Reference16 articles.

1. Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation

2. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States.;Baker WL;J Manag Care Pharm,2009

3. New oral anticoagulants: A view from the laboratory

4. Dabigatran versus Warfarin in Patients with Atrial Fibrillation

5. Apixaban versus Warfarin in Patients with Atrial Fibrillation

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Andexanet Alfa–Induced Heparin Resistance: Sustained Anticoagulant Inefficacy Despite Antithrombin Therapy;Journal of Cardiothoracic and Vascular Anesthesia;2024-08

2. Acute Aortic Dissection Managed with Nafamostat for Heparin Resistance in the Presence of DOAC Reversal Agent: a Case Report;Japanese Journal of Cardiovascular Surgery;2024-05-15

3. Andexanet Alfa Neutralizes the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin Almost as Protamine Sulfate;Clinical and Applied Thrombosis/Hemostasis;2024-01

4. Grundlagen zur Anwendung von Andexanet;Hämostaseologie;2023-10-09

5. Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study;Western Journal of Emergency Medicine;2023-09-13